Benitec Biopharma’s (BNTC) Buy Rating Reiterated at HC Wainwright

Benitec Biopharma (NASDAQ:BNTC)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $28.00 price target on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 90.87% from the stock’s previous close.

A number of other research analysts have also weighed in on BNTC. Guggenheim reaffirmed a “buy” rating and issued a $17.00 price target on shares of Benitec Biopharma in a research note on Tuesday, December 3rd. Robert W. Baird started coverage on shares of Benitec Biopharma in a report on Friday, December 13th. They set an “outperform” rating and a $30.00 price objective on the stock. Finally, Baird R W raised shares of Benitec Biopharma to a “strong-buy” rating in a research note on Thursday, December 12th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Benitec Biopharma has a consensus rating of “Buy” and a consensus price target of $24.43.

Benitec Biopharma Stock Up 2.3 %

BNTC opened at $14.67 on Monday. The stock has a market cap of $344.03 million, a P/E ratio of -9.72 and a beta of 0.92. Benitec Biopharma has a 12 month low of $4.75 and a 12 month high of $16.90. The company has a fifty day simple moving average of $12.07 and a 200 day simple moving average of $11.05.

Benitec Biopharma (NASDAQ:BNTC) last announced its quarterly earnings results on Friday, February 14th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.19. On average, equities research analysts expect that Benitec Biopharma will post -1.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Benitec Biopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Acuta Capital Partners LLC bought a new position in shares of Benitec Biopharma in the 3rd quarter valued at about $274,000. Ameriprise Financial Inc. boosted its position in Benitec Biopharma by 138.4% during the fourth quarter. Ameriprise Financial Inc. now owns 35,476 shares of the biotechnology company’s stock valued at $448,000 after purchasing an additional 20,597 shares during the last quarter. 683 Capital Management LLC bought a new position in Benitec Biopharma in the fourth quarter valued at approximately $452,000. Northern Trust Corp increased its position in shares of Benitec Biopharma by 54.2% during the 4th quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company’s stock worth $482,000 after purchasing an additional 13,425 shares during the last quarter. Finally, MYDA Advisors LLC bought a new stake in shares of Benitec Biopharma during the 4th quarter worth approximately $632,000. 52.19% of the stock is currently owned by institutional investors and hedge funds.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.